# Vaccine Therapy With Tumor Specific Mutated VHL Peptides in Adult Cancer Patients With Renal Cell Carcinoma

> **NCT00001703** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 6 (actual)

## Conditions studied

- Renal Cell Carcinoma

## Interventions

- **BIOLOGICAL:** incomplete Freund's adjuvant
- **BIOLOGICAL:** von Hippel-Lindau peptide vaccine

## Key facts

- **NCT ID:** NCT00001703
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 1998-08
- **Primary completion:** 2008-11
- **Final completion:** 2008-11
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Due to poor accrual and lack of peptide vaccine
- **Last updated:** 2014-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00001703

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00001703, "Vaccine Therapy With Tumor Specific Mutated VHL Peptides in Adult Cancer Patients With Renal Cell Carcinoma". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT00001703. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*